As­traZeneca caps its big win in lung can­cer with pos­i­tive sur­vival da­ta for Imfinzi — and what a re­lief it is

As­traZeneca capped its big win on the land­mark PA­CIF­IC study to­day with the news that its PD-L1 check­point Imfinzi de­liv­ered a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in over­all sur­vival for a key seg­ment of the lung can­cer mar­ket. 

The OS score dur­ing an in­ter­im analy­sis is for pa­tients whose stage III non-small cell lung can­cer hasn’t pro­gressed af­ter chemora­di­a­tion and whose tu­mors can’t be sur­gi­cal­ly re­moved. The da­ta here — specifics will fol­low at a con­fer­ence — will help As­traZeneca con­sol­i­date a cru­cial lead spot for it­self, which As­traZeneca CEO Pas­cal So­ri­ot has boast­ed will put the phar­ma gi­ant in the lead for “half the pool in lung can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER